ConductScience.org, home

Comparison · NCT02175225-98201e60

Deferoxamine Mesylate vs Normal Saline: Proportion of Patients With Modified Rankin Scale (mRS) Score 0-3 at 180 Days

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Deferoxamine Mesylate vs Normal Saline: Proportion of Patients With Modified Rankin Scale (mRS) Score 0-3 at 180 Days. Trial comparisons, record NCT02175225-98201e60. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02175225-98201e60

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.7190.6370.788wilson
Risk in group 20.6810.5990.754wilson
Risk difference, group 1 minus group 20.037-0.07180.145newcombe hybrid score
Risk ratio, group 1 over group 21.050.9021.23log
Odds ratio, group 1 over group 21.190.7082.01log
Number needed to treat, for one more participant with the outcome on Deferoxamine Mesylate than on Normal Saline27from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Deferoxamine MesylateDeferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days~Deferoxamine Mesylate97135OG000
Group 2Normal SalineNormal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days~Placebo (for Deferoxamine Mesylate)92135OG001

Outcome

Type
SECONDARY
Title
Proportion of Patients With Modified Rankin Scale (mRS) Score 0-3 at 180 Days
Description
Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome.
Time frame
180 days
Population
Per the SAP, the target population is the modified intention-to-treat population, including only subjects in whom study infusion is initiated. Complete case analysis was planned as the primary analytic approach.

Source ClinicalTrials.gov

Trial

Title
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
NCT number
NCT02175225
Phases
PHASE2
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine Mesylate, Placebo (for Deferoxamine Mesylate)
Lead sponsor
Beth Israel Deaconess Medical Center
Results first posted
2019-05-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02175225-98201e60